Continuous renal replacement therapy in the adult intensive care unit: History and current trends

Critical Care Nurse

Volumn 27, Issue 2, 2007, Pages 61-80

  Dirkes, Susan ^a,c   Hodge, Kimberly ^b  

^a NxStage Medical Inc   (United States)

^b Emergency Response Training Institute   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ACUTE KIDNEY FAILURE; ADULT; EQUIPMENT DESIGN; FLUID THERAPY; HEMODIAFILTRATION; HEMOFILTRATION; HUMAN; INSTRUMENTATION; INTENSIVE CARE; METHODOLOGY; MORTALITY; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; PATIENT CARE PLANNING; PATIENT SELECTION; PATIENT TRANSPORT; RENAL REPLACEMENT THERAPY; REVIEW;

ADULT; ANTICOAGULANTS; EQUIPMENT DESIGN; FLUID THERAPY; HEMODIAFILTRATION; HEMOFILTRATION; HUMANS; INTENSIVE CARE; KIDNEY FAILURE, ACUTE; NURSE'S ROLE; NURSING ASSESSMENT; PATIENT CARE PLANNING; PATIENT SELECTION; RENAL DIALYSIS; TRANSPORTATION OF PATIENTS;

EID: 34249713627     PISSN: 02795442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Jorres A. Acute renal failure: extracorporeal treatment strategies. Minerva Med. 2002;93:329-394.
2. Mueller BA, Krause MA, Ronco C, Clark, WR. Considerations in the management of patients in acute renal failure. In: Hörl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF, eds. Replacement for Renal Function by Dialysis. 5th ed. Norwell, Mass: Kluwer Academic Publishers; 2004:1181-1202.
3. Clermont G, Acker CG, Angus DC, Sirio CA, Pinsky MR, Johnson JP. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int. 2002;62:986-996.
4. Siegel N, Shah S. Acute renal failure: directions for the next decade. J Am Soc Nephrol. 2003;14:2176-2177.
5. Schetz M. Renal replacement therapy in patients with chronic (end-stage) renal failure and acute illness. In: Hörl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF, eds. Replacement for Renal Function by Dialysis. 5th ed. Norwell, Mass: Kluwer Academic Publishers; 2004:1139-1153.
6. Mehta RL, Pascual MT, Soroko S, Chertow GM, PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547-2553.
7. Shilliday IR, Quinn KJ, Allison MEM. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant. 1997;12:2592-2596.
8. Gutch CF. Principles of hemodialysis. In: Gutch CF, Stoner MH, Corea AL. Review of Hemodialysis for Nurses and Dialysis Personnel. 6th ed. St Louis, Mo: Mosby; 1999:45.
9. Cerda J, Bunchman TE, Gardner A, Hass J. Hospital reimbursement and cost benefit of CRRT [abstract]. Blood Purif. 2003;21:203-204. Abstract Doi 10-1159/000069158.
10. Schortgen F, Soubrier N, Delclaux C, et al. Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: usefulness of practice guidelines. Am J Respir Crit Care Med. 2000;162:197-202.
11. Gaspar LJ, Moreira NM, Moutinho AA, Moreira PJ, Lima HB. Continuous renal replacement therapies. EDTNA ERCA J. 2002;suppl 2;19-22.
12. Brady H, Brenner B, Clarkston M, Lieberthal W. Acute renal failure. In: Brenner BM, Rector FC, eds. Brenner and Rector's The Kidney. Vol 2. 6th ed. Philadelphia, Pa: WB Saunders Co; 2000:1201-1262.
13. Manns B, Doig, CJ, Lee H, et al. Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery. Crit Care Med. 2003;31:449-455.
14. Palevsky PM, Baldwin I, Davenport A, Goldstein S, Paganini E. Renal replacement therapy and the kidney: minimizing the impact of renal replacement therapy on recovery of acute renal failure. Curr Opin Crit Care. 2005;11:548-554.
15. Demirkilic U, Kuralay E, Yenicesu M, et al. Timing of replacement therapy for acute renal failure after cardiac surgery. J Card Surg. 2004;19:17-20.
16. Swartz RD, Messana JM, Orzol S, Port FK. Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure. Am J Kidney Dis. 1999; 34:424-432.
17. Price C. Continuous renal replacement therapy. In: Parker J, ed. Contemporary Nephrology Nursing. Pitman, NJ: Anthony Jannetti Publishing; 1998:579-587.
18. Kramer P, Wigger W, Reiger J, Matthaei D, Scheler F. Arteriovenous haemofiltration: a new and simple method for treatment of over-hydrated patients resistant to diuretics [in German]. Klin Wochenschr. 1977;55: 1121-1122.
19. Manns M, Sigler M, Teehan B. Continuous renal replacement therapies: an update. Am J Kidney Dis. 1999;32:185-207.
20. Locatelli F, Di Filippo S, Pontoriero G. Fluid and electrolyte balance during extracorporeal therapies. In: Ronco C, Bellomo R, eds. Critical Care Nephrology. Norwell, Mass: Kluwer Academic Publishers; 1998:249-259.
21. Ronco C, Paolo M, Bowry G, Bowry SK. Membranes for hemodialysis. In: Hörl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF, eds. Replacement for Renal Function by Dialysis. 5th ed. Norwell, Mass: Kluwer Academic Publishers; 2004:301-323.
22. Schmaldienst S, Hörl WH. The biology of hemodialysis. In: Hörl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF, eds. Replacement for Renal Function by Dialysis. 5th ed. Norwell, Mass: Kluwer Academic Publishers; 2004:157-179.
23. Chelamcharia M, Leypoldt JK, Cheung AK. Dialyzer membranes as determinants of the adequacy of dialysis. Semin Nephrol. 2005; 25:81-89.
24. Clark WR, LeBlanc M, Levin N. The Acute Dialysis Quality Initiative, IV: membranes for CRRT. Adv Ren Replace Ther. 2002;9:265-267.
25. Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int. 1999;56:2005-2015.
26. Johnson CA, Simmons WD. Dialysis of Drugs. City, State: Nephrology Pharmacy Associates Inc; 2002:1-9.
27. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999;10:846-853.
28. Morgera S, Slowinski T, Melzer C, et al. Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis. 2004;43:444-453.
29. Schindler R, Senf R, Frei U. Influencing the inflammatory response of hemodialysis patients by cytokine elimination using large pore membranes. Nephrol Dial Transplant. 2002;17:17-19.
30. Clark WR, Winchester JF. Middle molecules and small-molecular-weight proteins in ESRD: properties and strategies for their removal. Adv Ren Replace Ther. 2003;10:270-278.
31. Ronco C, Bellomo R. Nomenclature for renal replacement therapies. In: Ronco C, Bellomo R, eds. Critical Care Nephrology. Norwell, Mass: Kluwer Academic Publishers; 1998: 1169-1176.
32. Cole L, Bellomo R, Davenport P, Tipping P, Ronco C. Cytokine removal during continuous renal replacement therapy: an ex vivo comparison of convection and diffusion. Int J Artif Organs. 2004;27:388-397.
33. Tetta C, D'Intini V, Bellomo R, et al. Extracorporeal treatments in sepsis: are there new perspectives? Clin Nephrol. 2003; 60:299-304.
34. Schetz M, LeBlanc M, Murray PT. The Acute Dialysis Quality Initiative, VII: fluid composition and management in CRRT. Adv Ren Replace Ther. 2002;9:2282-2289.
35. Clark WR, Turk JE, Kraus MA, Gao D. Dose determinants in continuous renal replacement therapy. Artif Organs. 2003;27:815-820.
36. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Pre-dilution vs post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract. 2003;94:c83-c84.
37. Ronco C, Bellomo R. Principles of solute clearance during continuous renal replacement therapy. In: Ronco C, Bellomo R, eds. Critical Care Nephrology. Norwell, Mass: Kluwer Academic Publishers; 1998:1213-1223.
38. Ledebo I. Convective therapies, current status and perspectives. Ther Aphre Dial. 2005; 9:223-227.
39. Ronco C, Levin NW. Mechanism of solute transport in extracorporeal therapies. Contrib Nephrol. 2005;149:10-17.
40. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34:486-492.
41. Ronco C, Ricci Z, Bellomo R. Importance of increased ultrafiltration volume and impact on mortality: sepsis and cytokine story and the role for CVVH. EDTNA ERCA J. 2002; suppl 2:13-18.
42. Kierdorf HP, Leue C, Arns S. Lactate- or bicarbonate-buffered solutions in continuous extracorporeal renal replacement therapies. Kidney Int Suppl. November 1999: S32-S36.
43. Ronco C, Brendolan A, Bellomo R. Dialysis techniques: continuous renal replacement therapies. In: Hörl WH, Koch KM, Lindsay RM, Ronco C, Winchester JF, eds. Replacement for Renal Function by Dialysis. 5th ed. Norwell, Mass: Kluwer Academic Publishers; 2004:699-708.
44. Martin RL. Continuous renal replacement therapies. In: Lynn-McHale Wiegand DJ, Carlson KK, eds. AACN Procedure Manual for Critical Care. 5th ed. St. Louis, Mo: WB Saunders Co; 2005:937-960.
45. Dunham CM. Clinical impact of continuous renal replacement therapy on multiple organ failure. World J Surg, 2001;25:669-676.
46. Wang H, Zhang ZH, Yan XW, et al. Amelioration of hemodynamics and oxygen metabolism by continuous venovenous hemofiltration in experimental porcine pancreatitis. World J Gastroenterol. 2004; 11:127-131.
47. Goldstein SL, Currier H, Graf Cd, Cosio CC, Brewer ED, Sachdeva R. Outcome in children receiving continuous venovenous hemofiltration. Pediatrics. 2001;107:1309-1312.
48. Foland JA, Fortenberry JD, Warshaw BL, et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med. 2004;32:1771-1776.
49. Venkataraman R, Kellum JA, Palevsky P. Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States. J Crit Care. 2002;17:246-250.
50. Luyckx NA, Bonavente JV. Dose of dialysis in acute renal failure. Semin Dial. 2004; 17:30-34.
51. Tobe SW, Aujla P, Walele AA, et al. A novel citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care. 2003;18:121-129.
52. Davenport A, Mehta S. The Acute Dialysis Quality initiative, VI: access and anticoagulation in CRRT. Adv Ren Replace Ther. 2002; 9:273-281.
53. Dorval M, Madore F, Geadeh D, LeBlanc M. Citrate anticoagulation monitoring: postfilter ACT or ionized calcium? Blood Purif. 2002;20:305-323.
54. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med. 2006;32:188-202.
55. Davenport A. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy. Am J Kidney Dis. 1998;32:E3.
56. Hirsch J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004;164:361-369.
57. Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol. 2003;16:566-571.
58. Moffett DF, Moffett SB, Scauf L. Human Physiology: Foundations and Frontiers. St. Louis, Mo: Mosby Year Book Inc; 1993:398.
59. Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm. 2005;62:1663-1682.
60. Palsson R, Laliberte KA, Niles JL. Choice of replacement solution and anticoagulation in continuous venovenous hemofiltration. Clin Nephrol. 2006;65:34-42.
61. Cointault O, Kamar N, Bories P, et al. Regional citrate anticoagulation in venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transplant. 2004; 19:171-178.
62. Rocktaschel J, Morimatsu H, Uchino S, Ronco C, Bellomo R. Impact of continuous venovenous hemofiltration in acid-base balance. Int J Artif Organs. 2003;26:19-25.
63. Morgera S, Scholle C, Voss G, et al. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract. 2004;97:c131-c136.
64. Mehta R. Anticoagulation for continuous renal replacement therapy. In: Ronco C, Bellomo R, eds. Critical Care Nephrology. Norwell, Mass: Kluwer Academic Publishers; 1998:1181-1202.
65. Baldwin I, Bridge N, Elderkin T. Nursing issues, practices, and perspectives for the management of continuous renal replacement therapy in the intensive care unit. In: Ronco C, Bellomo R, eds. Critical Care Nephrology. Norwell, Mass: Kluwer Academic Publishers; 1998:1199-1211.
66. Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg. 2004;107:1-16.
67. Kyles DM. Coagulopathy and transfusion. In: Schell HM, Puntillo KA, eds. Critical Care Nursing Secrets. 2nd ed. St. Louis, Mo: Mosby Inc: 2006:432-445.
68. Gordon P. Post-resuscitation care. In: Kinney MR, Dunbar SB, Brooks-Brunn JA, Molter N, Vitello-Cicciu JM. AACN Clinical Reference for Critical Care Nursing. 4th ed. St. Louis, Mo: Mosby Inc: 1998:199-217.
69. LeBlanc M, Bosc JY, Paganini EP, Canaud B. Central venous dialysis catheter dysfunction. Adv Ren Replace Ther. 1997;4:377-389.
70. Balta Salai P. Hemodialysis. In: Parker J, ed. Contemporary Nephrology Nursing. Pitman, NJ: Anthony J Jannetti Inc; 1998:527-576.
71. Giuliano KK, Pysznik EE. Renal replacement therapy in critical care: implementation of a unit-based continuous venovenous hemodialysis program. Crit Care Nurse. February 1998;18:40-51.
72. Hoste EA, Blot SI, Lameire NH, Vanholder RC, De Bacquer D, Colardyn FA. Effect of nosocomial bloodstream infection on the outcome of critically ill patients with acute renal failure treated with renal replacement therapy. J Am Soc Nephrol. 2004;15:454-462.
73. Druml W. Metabolic aspects of continuous renal replacement therapies. Kidney Int Suppl. November 1999:S56-S61.
74. Jones SK. Loss of body heat during continuous venovenous hemodialysis (CVVHD) in critically ill patients. Blood Purif. 2003; 21:183-207.
75. Yagi N, LeBlanc M, Sakai K, Wright EJ, Paganini EP. Cooling effect of continuous renal replacement therapy in critically ill patients. Am J Kidney Dis. 1998;32:1023-1030.
76. Rickard CM, Couchman BA, Hughes M, McGrail MR. Preventing hypothermia during continuous veno-venous haemodiafiltration: a randomized controlled trial. J Adv Nurs. 2004;47:393-400.
77. Wolberg AS, Meng ZH, Monroe DM III, Hoffman M. A systemic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma. 2004;56:1221-1228.
78. Bent P, Tan HK, Bellomo R, et al. Early and intensive continuous hemofiltration for severe renal failure after cardiac surgery. Ann Thorac Surg. 2001;71:832-837.
79. von Bommel RF. Renal replacement therapy for acute renal failure on the intensive care unit: coming of age? Neth J Med. 2003; 61:239-248.
80. Gettings LG, Reynolds HN, Scalea T. Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs late. Intensive Care Med. 1999;25:805-813.
81. Bouman CS, Oudemans-van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002;30:2205-2211.
82. Paganini E, Depner T, Wensley D. The Acute Dialysis Quality Initiative, III: solute control (treatment dose). Adv Ren Replace Ther. 2002;9:260-264.
83. Palevsky PM, O'Connor T, Zhang JH, Star RA, Smith MW. Design of the VA/ NIH Acute Renal Failure Trial Network (ATN) study: intensive versus conventional renal support in acute renal failure. Clin Trials. 2005;2:423-435.
84. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. EDTNA ERCA J. 2002;Suppl 2;7-12.
85. Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis. 2000;36:294-300.
86. Kielstein JT, Kretschmer U, Ernst T, et al. Efficacy and cardiovascular tolerability of extended daily dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis. 2004;43:342-349.
87. O'Reilly P, Tolwani A. Renal replacement therapy III: IHD, CRRT, SLED. Crit Care Clin. 2005;21:367-378.
88. Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000;28:3581-3587.
89. Ratanarat R, Brendolan A, Piccinni P, et al. Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care. 2005; 9:R294-R302.
90. Piccinni P, Dan M, Barbacini S, et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med. 2006;32:80-86.
91. Schetz M. Non-renal indications for continuous renal replacement therapy. Kidney Int. Suppl. November 1999;S88-S94.
92. Honore PM, Matson JR. Hemofiltration, adsorption, sieving and the challenge of sepsis therapy design. Crit Care. 2002;6:394-396.
93. Ronco C, Inguaggiato P, D'Intini V, et al. The role of extracorporeal therapies in sepsis. J Nephrol. 2003;16(suppl 7):S34-S41.
94. Kellum JA, Song M, Ventakaraman R. Hemoadsorption removes tumor necrosis factor, interleukin 6, and interleukin 10, reduces nuclear factor β DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med. 2004;32:801-805.
95. Song M, Winchester J, Albright RL, Capponi VJ, Choquette MD, Kellum JA. Cytokine removal with a novel adsorbent polymer. Blood Purif. 2004;22:428-434.
96. Kellum JA, Ventakaraman R. Application of blood purification to non-renal organ failure. Int J Artif Organs. 2005;28:445-449.
97. Winchester JF, Silborzweig J, Ronco C, et al. Sorbents in acute renal failure and end-stage renal disease: middle molecule and cytokine removal. Blood Purif. 2004;22:72-77.
98. Bellomo R, Tetta C, Brendolan A, Ronco C. Coupled plasma filtration adsorption. Blood Purif. 2002;20:289-292.
99. Berlot G, Tomasini A, Silvestri L, Gullo A. Plasmapheresis in the critically ill patient. Kidney Int Suppl. 1998;66:S178-S181.
100. Ronco C, Ricci Z, Brendolan A, Bellomo R, Bedogni F. Ultrafiltration in patients with hypervolemia and congestive heart failure. Blood Purif. 2004;22:150-163.
101. Grapsa E, Alexopoulos GP, Margari Z, Terrovitis JV, Kontoyannis DA, Nanas JN. Ultrafiltration in the treatment of severe congestive heart failure. Int Urol Nephrol. 2004;36:269-272.
102. Clark WR, Paganini E, Weinstein D, Bartlett R, Sheinfeld G. Ronco C. Extracorporeal ultrafiltration for acute exacerbations of chronic heart failure: report from the Acute Dialysis Quality Initiative. Int J Artif Organs. 2005;28:466-476.
103. Humes HD, Weitzel WF, Bartlett RH, et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int. 2004; 66:1578-1588.
104. Tiranathanagul K, Eiam-Ong S, Humes HD. The future of renal support: high-flux dialysis to bioartificial kidneys. Crit Care Clin. 2005;21:379-394.
105. de Francisco AL, Pinera C. Challenges and future of renal replacement therapy. Hemodial Int. 2006;10(suppl 1):S19-S23.
106. Augustine JJ, Sandy D, Seifert TH, Paganini EP. A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF. Am J Kidney Dis. 2004; 44:1000-1007.
107. Teehan GS, Liangos O, Jaber BL. Update on dialytic management of acute renal failure. Intensive Care Med. 2003;18:130-138.